3 results
Approved WMOCompleted
To assess the immunomodulatory effects of erythromycin and clindamycin in healthy volunteers.
Approved WMOWill not start
This study will evaluate the efficacy of brentuximab vedotin in combination with lenalidomide and rituximab among subjects with relapsed or refractory CD30-positive (CD30 expression >=1%) or CD30 <1% (CD30 expression <1%) DLBCL.
Approved WMOPending
Main Phase:To demonstrate the superiority of medium-dose BDP/FF/GB pMDI compared to high-dose BDP/FF pMDI in terms of the proportion of subjects exhibiting on average NPAL over 26 weeks of treatment in the study sub-population with PAL at screening…